Cara Therapeutics Inc. (NASDAQ: CARA) showing jumped of 5.89% and closed at $16.17, after gaining total volume of 1.37 million shares. Its earnings per share (EPS) is -$2.10 and its beta value stands at 3.20 points and has total market capitalization of $430.77 million and a total of 27.30 million outstanding shares.
Cara Therapeutics Inc. (CARA) on March 10, 2017 announced financial results for the fourth quarter and full year ended December 31, 2016.
“In 2016, we advanced our three late-stage trials in indications of high unmet need where existing therapies are ineffective or are limited by significant side effects and the high potential for abuse,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “We look forward to a transformative 2017, as we anticipate sharing efficacy